Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]

Donanemab Label Update: What the Modified Titration Data Means for Clinicians: John Sims, MD

Articles

Collateral Damage to Patients From Formulary Restrictions in Multiple Sclerosis (MS): Perspectives from an MS Specialist, a Patient, and a Neurologist in Training

The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]

Overviewing the Conduct and Rationale Behind Donanemab’s TRAILBLAZER-ALZ 6 Study: John Sims, MD

The FDA-cleared duo devices allow for a more simplified administration of the liquid medicine Hyqvia, reducing the number of steps needed to prepare for the infusion of 2 dual vial units or more. 

FDA Clears HyHub and HyHub Duo Devices for Easier Administration of Immune Globulin Infusion, Hyqvia 

William E. Murray Professor of Neurology in the Movement Disorders Division at the Medical University Of South Carolina.

A duo of experts discussed a novel hybrid trial approach combining in-home video assessments with traditional visits to improve Parkinson disease research participation and assess a new investigational therapy. [WATCH TIME: 7 minutes]

Designing a Hybrid Trial of Bezisterim for Early-Stage Parkinson Disease: Mark Stacy, MD; Joseph M. Palumbo, MD, LFAPA, MACPsych

The associate professor of neurology at Johns Hopkins detailed how artificial intelligence is shaping the future of neurology through its integration in clinical care, research, and medical education. [WATCH TIME: 4 minutes]

Preparing the Neurology Workforce for an AI-Integrated Future: Elisabeth Marsh, MD

Assistant professor of neurology at the Icahn School of Medicine at Mount Sinai.

At AHS 2025, the assistant professor of neurology at the Icahn School of Medicine at Mount Sinai highlighted the challenges LGBTQIA+ individuals may face in migraine care. [WATCH TIME: 6 minutes]

Addressing the Migraine Care Needs of the LGBTQIA+ Patient Population: Anna Pace, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Elisabeth Marsh, MD, an associate professor of neurology at Johns Hopkins, shared her insights on the emerging role of AI in clinical practice and neurologic education, ahead of her session at the 2025 ANA/AUPN Annual Meetings. 

Rethinking Neurology Education With AI: A Preview of ANA/AUPN 2025

The multiple sclerosis condition center is a resource for clinical news on the diagnosis, treatment, and management of multiple sclerosis. | NeurologyLive.


Multiple Sclerosis | Clinical Neurology News | NeurologyLive

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1.125rem

Clinical

 MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

In this episode, "Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis," Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the new McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 

40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

. Ontaneda, who also serves as an assistant professor of neurology, discussed the most notable changes to the criteria and how it may help towards improving rates of misdiagnosis and missed diagnosis. He spoke on the incorporation of new biomarkers, such as central vein sign and paramagnetic rim lesions, and the ability to diagnose MS in stages before clinical presentation shows. Furthermore, Ontaneda gave some perspective on the areas of the new criteria that will take some time to adjust to, as well as how these criteria may change the philosophical perspective of the disease as a whole.


The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Potential Regulatory Submission for Inebilizumab in Myasthenia Gravis Following Positive Phase 3 MINT Data

Parkinson Agent Tavapadon Meets Primary and Secondary End Points as Monotherapy in Phase 3 TEMPO-1 Trial

Sage Therapeutics and Biogen Officially Announce Ending of SAGE-324 Program in Essential Tremor

 – Focus and direction of new diagnostic criteria

 – Overviewing specific changes to McDonald criteria

 – Approach to diagnosing pre-MS; treating radiologically isolated syndrome earlier

 – Incorporation of new biomarkers, central vein sign, paramagnetic rim lesions, OCT

 – Unanswered questions/challenges left out of the diagnostic criteria

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

European Committee for Treatment and Research in Multiple Sclerosis Congress (ECTRIMS)

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 27 minutes]

Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

Episode 47, "Incorporating Physical Therapy Into MS Care," features an exclusive interview with Patricia Bobryk, MHS, PT, MSCS, ATP, physical therapist, UC Health, and cochair, 

International Organization of MS Rehabilitation Therapists (IOMSRT)

. Bobryk shared her insight into the clinical care of MS from the perspective of a rehabilitative specialist, and the importance of including physical therapy approaches as part of the multidisciplinary approach to care as early as possible to ensure more beneficial long-term outcomes for patients, also speaking to the latest advances and developments in rehabilitative medicine.

The stories feature in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Noncontact Boxing Exercise Assessed for Parkinson Disease Benefit

Opicapone Demonstrates Small Benefit for Sleep in Parkinson Disease

Amylyx Announces Plans to Submit NDA for AMX0035 for ALS

Episode Breakdown

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Patricia Bobryk, MHS, PT, MSCS, ATP.

Episode 47: Incorporating Physical Therapy Into MS Care

Episode 38, "Advancing MS Care and Awareness," features an interview with Barry Hendin, MD, clinical professor, University of Arizona; director, Multiple Sclerosis Clinic, Banner University Medical Center; and chief medical officer, Multiple Sclerosis Association of America. He shared his perspective on the recent World MS Day on May 30, the impact awareness efforts have had on care, and how treatment has evolved during his time as a multiple scleorsis (MS) physician.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Barry Hendin, MD.

Episode 38: Advancing MS Care and Awareness

A recent study reveals a decline in multiple sclerosis progression rates, highlighting the impact of improved treatments and the need for ongoing innovation in care.

30-Year Analysis Suggests Regression of Progressive Multiple Sclerosis, In Part to Advances in Therapeutics

Helius Medical Technologies expands access to its PoNS device for patients with MS as Aetna joins major payers in coverage, enhancing treatment options.

Aetna Joins UnitedHealthcare and Anthem in Authorizing PoNS Device Claims for Patients With MS

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.

NeuroVoices: Tiffany Malone, MSW, MSCS, on Combating Loneliness in MS Care Through Connection and Community Programs

Sam Hooshmand, DO, assistant professor of neurology at the Medical College of Wisconsin, discussed the complexities of defining, diagnosing, and managing advanced MS.

Clinical Insight on Challenges and Evolving Strategies in Advanced Multiple Sclerosis Care

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. 

Balancing MS Relapse Risk With Personalized Therapy Decisions: Gabrielle Macaron, MD

"I think patient support programs from pharmaceutical companies can be really helpful in making sure that at least the pretreatment workup and the ongoing monitoring is going as expected and that nothing falls through the cracks.”

Multiple sclerosis (MS) is considered one of the primary causes of nontraumatic neurological disability in young adult patients. Clinicians have advised early use of disease-modifying therapies (DMTs), along with consistent monitoring, for patients who are living with relapsing-remitting forms of the disease. Postponing treatment following a diagnosis could potentially lead to greater disease burden and increased societal health care costs. A wide range of DMT options are available for patients, which differ in administration method, efficacy, adverse effects, safety considerations, as well as cost.

According to a previous study published in 

, researchers reported that the most significant factor in choosing a DMT was its adverse effect profile, followed by its ability to delay disability progression. Findings also showed that patients' treatment preferences evolved based on their prior experiences with DMTs and the length of time since their diagnosis. The findings highlighted the importance of developing and selecting therapies that reflect patient preferences, which may lead to improved adherence and more effective long-term management of MS.

2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting

, held May 28-31, 2025, in Phoenix, Arizona, 

, gave a talk on the initial decision-making process for what DMT patients should start. During the meeting, Macaron, an assistant professor in the Department of Neuroscience at Université de Montréal, sat down with 

 to outline the dual risks of MS and its DMTs. In the interview, she highlighted the unpredictable nature of the disease and the value of early, high-efficacy treatment to reduce long-term disability, as well as discussed risk mitigation strategies and adapting treatment choices to patient lifestyles and preferences.

Click here for more coverage of CMSC 2025.

REFERENCES
1. Bansback N, Chiu JA, Metcalfe R, et al. Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin. 2021;7(3):20552173211029966. Published 2021 Jul 15. doi:10.1177/20552173211029966
2. Garcia-Dominguez JM, Muñoz D, Comellas M, Gonzalbo I, Lizán L, Polanco Sánchez C. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Prefer Adherence. 2016;10:1945-1956. Published 2016 Sep 26. doi:10.2147/PPA.S114619
3. Macaron G. Decision Making Process Around What DMT to Start. Presented at: 2025 CMSC Annual Meeting; May 28-31; Phoenix, AZ. Era of Too Many Choices: Starting and Switching. 2016;10:1945-1956. Published 2016 Sep 26. doi:10.2147/PPA.S114619

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed the implementation of digital platforms and lifestyle-focused clinics to streamline MS care.

Modernizing Multiple Sclerosis Care With Digital Tools and Holistic Clinical Approaches: Agne Straukiene, MD

“It means time is brain. Brain health is preserved because we are starting highly active disease-modifying therapy to preserve the brain health, to preserve the brain volume, and to give people life.”

Innovations may be essential in clinical practice to better serve patients with multiple sclerosis (MS), especially by potentially helping to reduce delays in diagnosis and treatment. A recently published study in 

Multiple Sclerosis Journal – Experimental, Translational and Clinical

 assessed real-world impact of digital technologies and holistic care strategies for patients with MS implemented at a UK center. In the study, researchers included personal health records and educational apps for patients with MS, clinical databases and disease progression tools for health care providers, and the introduction of a Healthy Lifestyle Clinic aimed at promoting brain health.

, the study compared patient outcomes before and after implementing these interventions between 2018 and 2023. Overall, findings revealed a significant reduction in the time from diagnosis to starting disease-modifying therapy, dropping from about 24 months to under 6 months. Unsurprisingly, researchers observed that patients with delayed diagnoses were more likely to experience disease progression. Additionally, nonelective hospital admissions and healthcare costs decreased compared with nearby hospitals. Altogether, these results suggest that combining digital tools with holistic care approaches can improve MS care delivery, though authors noted that further research may be needed to confirm these trends.

, Straukiene, a consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust, described how the integration of digital tools could transform MS care delivery, based on findings from the study. She explained how these innovations could support earlier detection of disease progression and greater patient engagement. In addition, Straukiene talked about how the Healthy Lifestyle Clinic, which offers a patient-centered, group-based setting that focuses on diet, exercise, emotional well-being, and social support, can possibly promote timely clinical decisions and also improve health outcomes for people living with MS.

REFERENCES
1. Straukiene A, Hughes S, Grundy J, Moxon F. Evaluating patient care in multiple sclerosis: Impact of combined digital tools and holistic management strategies. Mult Scler J Exp Transl Clin. 2025;11(2):20552173251317020. Published 2025 Apr 15. doi:10.1177/20552173251317020

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed the implementation of digital platforms and lifestyle-focused clinics to streamline MS care. [WATCH TIME: 5 minutes]

The associate vice president of strategy and innovation at the National MS Society highlighted the measurable benefits of health and wellness coaching for individuals with multiple sclerosis. 

Exploring the Clinical Impact of Health and Wellness Coaching in MS Care: Cassandra Moore, MPH, CPH

“Health and wellness coaches really support people in achieving their self-directed goals and behavioral changes that are informed by any treatment plans prescribed by the rest of the professional health care team.”

Health coaching, which focuses on improving self-management and overall well-being, has been explored as a supportive approach for patients with living multiple sclerosis (MS). Through regular, goal-oriented conversations, health coaches have the ability to work alongside patients to help them with addressing some of the physical, mental, and behavioral aspects of living with the autoimmune disease. Recent research has suggested that health coaching may contribute to improvements in areas such as self-efficacy, quality of life, and symptom management, although the extent of these benefits can vary.

In clinical practice, health coaching can be offered as a complementary resource in combination with traditional medical care by helping patients coordinate and integrate various aspects of their treatment plans. For patients with MS, coaching may provide additional support in managing the disease’s complex symptoms and making lifestyle adjustments. The effectiveness of health coaching can depend on a variety of factors such as patient readiness, engagement, and the timing of the intervention in the disease course. Further research could be needed to grasp a better understanding of the role and impact of health coaching in MS care.

, held May 28-31, 2025, in Phoenix, Cassandra Moore, MPH, CPH, associate vice president of strategy and innovation at the 

, presented a talk on the power of health coaching in MS.

 Following the meeting, Moore sat down with 

 to further discuss the growing evidence supporting health and wellness coaching for individuals with MS. In the interview, Moore shared firsthand experiences from coaching cohorts, where participants reported increased self-efficacy and meaningful behavioral changes. She underscored the value of coaching in bridging gaps between specialties, enhancing care coordination, and empowering patients with MS.

REFERENCES
1. Boehmer KR, Álvarez-Villalobos NA, Barakat S, et al. The impact of health and wellness coaching on patient-important outcomes in chronic illness care: A systematic review and meta-analysis. Patient Educ Couns. 2023;117:107975. doi:10.1016/j.pec.2023.107975
2. Kivelä K, Elo S, Kyngäs H, Kääriäinen M. The effects of health coaching on adult patients with chronic diseases: a systematic review. Patient Educ Couns. 2014;97(2):147-157. doi:10.1016/j.pec.2014.07.026
3. Moore C. The Power of Health Coaching. Presented at: 2025 CMSC Annual Meeting; May 28-31; Phoenix, AZ. Thriving with MS: Harnessing Wellness Research & the Power of Health Coaching.

The associate vice president of strategy and innovation at the National MS Society highlighted the measurable benefits of health and wellness coaching for individuals with multiple sclerosis. [WATCH TIME: 5 minutes]

SAP Partners

The assistant professor of neurology at the Medical College of Wisconsin talked about the complexities of advanced multiple sclerosis, highlighting gaps in clinical trials and the need for individualized care strategies. 

Challenges and Considerations in the Care Management of Advanced Stages of Multiple Sclerosis: Sam Hooshmand, DO

"Advanced MS is a particularly challenging entity, and we as neurologists need to advocate and work with our industry partners to try to include these patients in clinical trials to get the data we need to make better decisions in terms of disease-modifying therapies."

Advanced multiple sclerosis (MS), particularly secondary progressive MS (SPMS), is often characterized by insidious neurologic decline marked by increasing physical disability, cognitive dysfunction, and a significant symptom burden. Traditional tools like the Expanded Disability Status Scale (EDSS), commonly used by clinicians to assess disease progression, may underrepresent cognitive, bowel/bladder, and sensory deficits in later stages of the disease, symptoms that can precede overt motor deterioration.

 Therefore, early identification of these changes, aided by cognitive screening tools and digital assessments, may support more proactive care strategies before functional decline becomes pronounced in patients.

Besides the complexity of diagnosis, the management of advanced MS in clinical practice presents distinct challenges, largely because of the lack of definitive evidence from pivotal clinical trials, which have typically excluded patients with EDSS scores above 6.5. In a recent meta-analysis, findings suggested that disease-modifying therapies could offer some benefit in slowing progression in patients with progressive MS, though their use should possibly be carefully balanced against adverse risks.

 As a result, there is a growing clinical imperative to include more patients with advanced MS in trials and to tailor treatment approaches based on disease progression as well as individual risk-benefit considerations.

, an assistant professor of neurology at the Medical College of Wisconsin, spoke with 

on the lack of a universally accepted definition of advanced MS.

 Using aspects from his talk presented at the meeting, Hooshmand emphasized the limitations of using the EDSS score alone to assess disease progression and the significant impact of secondary complications on advanced MS. Furthermore, he highlighted the importance of personalized care that supports functional independence and noted the absence of patients with advanced MS in most disease-modifying therapy clinical trials.

REFERENCES
1. Pozzilli C, Pugliatti M, Vermersch P, et al. Diagnosis and treatment of progressive multiple sclerosis: A position paper. Eur J Neurol. 2023;30(1):9-21. doi:10.1111/ene.15593
2. Wu X, Wang S, Xue T, et al. Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials. Front Neurol. 2024;15:1295770. Published 2024 Mar 11. doi:10.3389/fneur.2024.1295770
2. Hooshmand S. Advanced Disease States in Multiple Sclerosis: A Clinical Perspective. Presented at: 2025 CMSC Annual Meeting; May 28-31; Phoenix, AZ. Whitaker Track Invited Lectures: MS in Special Populations.

The assistant professor of neurology at the Medical College of Wisconsin talked about the complexities of advanced multiple sclerosis, highlighting gaps in clinical trials and the need for individualized care strategies. [WATCH TIME: 3 minutes]

A patient and neurologist discussed personal and professional perspectives on treatment initiation, ongoing research, and patient advocacy in multiple sclerosis. 

Patient and Clinical Perspectives on Advancing MS Care Through Treatment, Advocacy, and Research

Early signs and symptoms of multiple sclerosis (MS) can be subtle and varied, often leading to initial misdiagnosis or delayed recognition. These may include visual changes, numbness, fatigue, or mood-related concerns, which can be mistaken for more common conditions. To reach an accurate diagnosis, clinicians typically rely on MRI imaging and other specialized tests to rule out alternative causes. Once MS is identified, shared decision-making between the patient and clinician may be essential, aiming to guide individualized treatment strategies and support long-term disease management.

 held a roundtable discussion with an MS expert and patient living with MS who talked about the early signs of the disease and the impeding challenges that can delay diagnosis. The featured guests included neurologist 

, director of the Multiple Sclerosis Experimental Therapeutics Program at John Hopkins Medicine, and 

, director of regulatory affairs at the National Multiple Sclerosis Society, who spoke on the importance of patient-clinician collaboration in navigating care and treatment planning.

In this final episode, Boschi and Mowry talked about the evolving landscape of MS care from both a patient and clinical-research perspective. Boschi, as a patient newly diagnosed with MS, shared her anticipation of starting treatment and her involvement in advocacy efforts with the Society, including work on Medicaid access and pharmacy benefit reform. Mowry highlighted ongoing advancements in MS research, particularly in progressive MS, and emphasized the importance of accurate diagnosis, rehabilitation strategies, and international collaboration. Both, in the conversation, underscored the value of community resources and a team-based approach to care.

: Thank you both for sharing your perspectives on this. Those are all the questions that I have for this discussion, unless there was anything else that you wanted to add to this conversation in terms of what you're looking forward to this year in the field of MS—or even on the patient advocacy side of things—what you're looking forward to there as well?

: Personally, I'm looking forward to just starting on treatment. I think the most anxiety-inducing place is knowing that you have this disease and not doing anything about it yet. So, I'm very excited to have my first treatment tomorrow. Professionally, as I do work for the National Multiple Sclerosis Society, there are so many interesting advocacy things going on. We're working on pharmacy benefit manager reform. We're working on being able to keep access to Medicaid for people who need it. There are so many interesting advocacy efforts, and I'm so glad to be part of it—and also to join the people living with MS who are our advocates. Now I'm one of them, and it's so empowering. I can't wait—we have our Hill Day next month, and I can't wait to go to the Hill with them and say, "Now I'm one of you, and we're in this together."

: Yeah. In addition to working with people with MS in the clinic, as I mentioned earlier, I spend a lot of time doing research, and so I feel lucky to be engaged with that community as well. I know there are people all around the world who are constantly thinking of new ideas, new potential treatments to test, designing the trials to test out those treatments and see if they help people with MS—new ways of trying to measure MS and quantify what's happened in people, so that it will enable that medication development. New ways of doing rehab, new ways of improving the diagnosis and the diagnostic criteria to make sure people are getting an accurate diagnosis so they can start on treatment in time.

A patient and neurologist discussed personal and professional perspectives on treatment initiation, ongoing research, and patient advocacy in multiple sclerosis. [WATCH TIME: 5 minutes]

Multiple Sclerosis

Latest News